Placeholder Banner

BIO Comments to FDA on Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products

October 27, 2023

BIO submits comments and specific recommendations to the U.S. Food and Drug Administration on their Draft Guidance for Industry (Docket No. FDA-2023-D-2436)

Download Full Comments Below
BIO Comment Letter - FDA-2023-D-2436
Discover More
BIO provided general comments and recommended edits Re: FDA-2023-D-3031
BIO joins 30 other national trade associations in speaking out against unprecedented and burdensome FTC-DOJ regulation of mergers
BIO submits comments in response to the agency’s request for information (FDA-2023-N-3742)